Pharmacologic activities of copper compounds in chronic diseases
J R Sorenson1, L W Oberley, R K Crouch
1Department of Biopharmaceutical Sciences, College of Pharmacy, USA.
Abstract:
Copper complexes have been shown to be effective antiinflammatory, antiulcer, anticonvulsant, anticancer, and antidiabetic agents. This seemingly diverse variety of pharmacologic effects is unified by the hypothesis that copper complexes facilitate or promote tissue repair processes involving copper-dependent enzymes and that arthritis, ulcers, seizures, neoplasia, and diabetes are diseases of specific tissues in disrepair. The corollary to this hypothesis is that the loss or reduction of copper-dependent enzyme-mediated processes leads to tissue dysfunction that may be reversed with copper complex therapy.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacogenomics: Identification of New Drug Targets


